Seaport Therapeutics, Inc. (SPTX)
Market Closed
15 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS) Primary $
17. 60
+0.92
+5.5156%
$
918.05M Market Cap
- P/E Ratio
- Div Yield
164,901 Volume
- Eps
$ 16.68
Previous Close Investors:
Want to track SPTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation
Seaport Therapeutics leverages its Glyph platform to transform clinically validated molecules with poor delivery into proprietary, patent-protected prodrugs, reducing biological risk. GlyphAllo's Phase 2b BUOY-1 trial in MDD targets a differentiated profile, with top-line data expected in H1 2027 and a focus on anxious distress subpopulations. GlyphAgo's strong Phase 1 PK data and platform repeatability support SPTX's strategy, with Phase 2a in GAD set for H2 2026 and registration-enabling studies to follow.
Seekingalpha | 2 months ago
2026 © Marketlog. All Rights Reserved.
